AYALA PHARMACEUTICALS INC (AYLA) Stock Income Statement
NASDAQ:AYLA - Nasdaq - US05465V1089 - Common Stock - Currency: USD
| TTM (2022-9-30) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.73M | 3.51M | 3.71M | 2.33M | 0.00 | |||
| Cost Of Goods | 1.64M | 3.51M | 3.71M | 1.29M | 0.00 | |||
| Gross Profit | 90.00K | 0.00 | 0.00 | 1.05M | 0.00 | |||
| Operating Expenses | 37.63M | 39.22M | 29.78M | 18.76M | 9.04M | |||
| Research and Development | 27.81M | 29.94M | 22.41M | 14.42M | 5.74M | |||
| Selling, General, and Administrative Expenses | 9.83M | 9.28M | 7.37M | 4.34M | 3.29M | |||
| Operating Income | -37.54M | -39.22M | -29.78M | -17.71M | -9.04M | |||
| Interest Income/Expense | -224.00K | -260.00K | 60.00K | 230.00K | 450.00K | |||
| Income Before Taxes | -37.77M | -39.48M | -29.72M | -17.49M | -8.59M | |||
| Income Tax | 708.00K | 776.00K | 430.00K | 310.00K | 290.00K | |||
| Net Income | -38.47M | -40.25M | -30.15M | -17.79M | -8.87M | |||
| EBITDA | -37.39M | -39.05M | -29.60M | -17.56M | -8.99M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.51 | -2.80 | -3.06 | -1.76 | -0.88 | |||
| Non GAAP EPS | -2.52 | -2.83 | -3.38 | N/A | N/A | |||
| Statistics | ||||||||
| Gross Profit Margin | 5.19% | N/A | N/A | 45.06% | N/A | |||
| Profit Margin | -2220.08% | -1148.15% | -812.67% | -763.52% | N/A | |||
| Operating Profit Margin | -2166.30% | -1118.60% | -802.70% | -760.09% | N/A | |||
All data in USD